Molecular Imaging Market Size & Growth Forecast 2026–2035, By Segments (Modality, End Use, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Molecular Imaging Market size was worth USD 9.1 Billion in 2025 and is expected to grow at a 4.6% CAGR between 2026 and 2035, reaching USD 14.27 Billion by 2035. The industry revenue for 2026 is estimated at USD 9.46 billion.
Get more details on this report
Request Free Sample ReportMolecular Imaging Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 43.88% of the market in 2025, driven by established imaging infrastructure, widespread clinical adoption, and strong utilization across oncology, cardiology, and neurology workflows.
- Asia Pacific is expected to grow at a 5.24% CAGR as healthcare infrastructure expands, diagnostic investments increase, and specialist care adoption drives greater use of molecular imaging.
Segment Momentum
- SPECT held a 45.9% market share in 2025 due to its broad clinical familiarity, integration with existing nuclear medicine infrastructure, and sustained use across routine diagnostic imaging workflows.
- Diagnostic imaging centers are growing fastest as healthcare shifts toward specialized outpatient services offering streamlined workflows, faster scheduling, and expanded access to molecular imaging outside hospital settings.
Market Expansion Drivers
- Rising chronic diseases such as cancer and neurological disorders increasing imaging demand.
- Growth of hybrid PET-SPECT/CT systems and AI-enabled imaging diagnostics.
- Expanding government and institutional funding for cancer research and radiology innovation.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Major companies in the molecular imaging market include Siemens Healthineers AG (Germany), GE HealthCare (United States), Koninklijke Philips N.V. (Netherlands), Canon Medical Systems Corporation (Japan), Bruker Corporation (United States), Shimadzu Corporation (Japan), Mediso Ltd. (Hungary), United Imaging Healthcare Co., Ltd. (China), Cubresa Inc. (Canada), Positron Corporation (United States).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
The growing burden of oncology and neurology cases is steadily increasing scan volumes, because clinicians rely on molecular imaging to detect disease activity earlier, characterize lesions more precisely, and monitor treatment response beyond what anatomical imaging alone can provide. In the molecular imaging market, this translates into stronger utilization of PET, SPECT, and related radiotracer-based procedures in diagnostic pathways where treatment decisions depend on metabolic or functional insight. As hospitals and specialty centers manage more patients requiring staging, recurrence assessment, and therapy follow-up, procurement priorities shift toward advanced imaging platforms, tracer access, and workflow capacity, reinforcing market demand through routine clinical use rather than one-time capital adoption.
Growth of hybrid PET-SPECT/CT systems and AI-enabled imaging diagnostics
Hybrid imaging systems are changing purchasing behavior by combining functional and anatomical information in a single workflow, improving diagnostic confidence while reducing the need for multiple separate exams. For the molecular imaging market, the appeal of PET/CT and SPECT/CT platforms lies in their ability to support more efficient clinical decision-making in oncology, cardiology, and neurology, which helps imaging providers justify premium equipment investments. AI-enabled imaging diagnostics adds another practical layer by assisting with image reconstruction, lesion detection, quantification, and reporting consistency, making advanced molecular imaging easier to scale in busy clinical settings and supporting market expansion through higher productivity and broader physician acceptance.
Expanding government and institutional funding for cancer research and radiology innovation
Public and institutional funding plays a direct role in shaping technology adoption by supporting radiotracer development, clinical research programs, imaging infrastructure upgrades, and translational work that moves new techniques into standard care. In the molecular imaging market, this funding reduces part of the commercialization risk for manufacturers and research centers, allowing more rapid validation of novel imaging agents and diagnostic applications tied to cancer management. It also strengthens referral confidence over time, because evidence generated through funded trials and academic partnerships influences treatment protocols, purchasing decisions, and the integration of molecular imaging into hospital-based precision medicine strategies.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising chronic diseases such as cancer and neurological disorders increasing imaging demand | 2.00% | High | North America, Europe | High | Near Term |
| Growth of hybrid PET-SPECT/CT systems and AI-enabled imaging diagnostics | 1.60% | High | North America, Asia Pacific | High | Mid Term |
| Expanding government and institutional funding for cancer research and radiology innovation | 1.30% | High | North America, Europe | High | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held the leading molecular imaging market position in 2025, accounting for a 43.88% share. This leadership is underpinned by the region’s established diagnostic imaging infrastructure, broad use of advanced imaging technologies in clinical settings, and the routine integration of molecular imaging into oncology, cardiology, and neurology workflows. In practice, strong hospital networks and specialized imaging centers support higher procedure volumes, while mature reimbursement and clinical adoption patterns help maintain steady utilization across both diagnosis and treatment monitoring.
Asia Pacific is projected to register a 5.24% CAGR over the forecast period in the molecular imaging market, backed by expanding healthcare infrastructure and rising access to advanced diagnostic services across major economies in the region. Growth is accelerating as hospitals and diagnostic providers increase investment in imaging systems to meet rising patient demand and improve disease detection capabilities. Practical adoption is also being strengthened by the gradual expansion of specialist care, which is increasing the use of molecular imaging in routine clinical decision-making and earlier-stage diagnostic pathways.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Clinical radiopharma workflowsGermany molecular imaging market is anchored in structured clinical pathways and strong radiopharmaceutical manufacturing alignment. In Germany, hospital networks emphasize standardized PET/SPECT protocols, with growing collaboration between research institutes and imaging equipment providers to improve diagnostic reproducibility and expand precision oncology applications within regulated healthcare environments.
France 🇫🇷
Nuclear medicine adoptionFrance molecular imaging market reflects strong public healthcare system integration with nuclear medicine services. In France, academic hospitals emphasize PET-based research in oncology and neurology, while adoption is guided by reimbursement frameworks that support targeted use of advanced imaging for complex diagnostic cases and treatment monitoring.
Italy 🇮🇹
Diagnostic center networksItaly molecular imaging market is characterized by specialized diagnostic centers and uneven regional access to advanced imaging infrastructure. In Italy, leading hospitals concentrate PET and SPECT capabilities in urban hubs, focusing on oncology diagnostics while gradually expanding radiopharmaceutical availability and improving inter-hospital referral imaging networks.
Japan 🇯🇵
Diagnostic miniaturization focusJapan molecular imaging market prioritizes compact, high-efficiency diagnostic systems suited to aging population care settings. In Japan, hospitals focus on rapid PET imaging workflows and integration with digital diagnostics platforms, while manufacturers emphasize lower-dose radiotracers and space-efficient scanner designs for urban healthcare infrastructure.
South Korea 🇰🇷
Hospital imaging digitizationSouth Korea molecular imaging market is shaped by rapid hospital digitization and strong adoption of advanced imaging IT systems. In South Korea, tertiary hospitals invest in integrated imaging networks linking nuclear medicine with electronic health records, improving diagnostic turnaround times and supporting expanding oncology screening programs.
United States 🇺🇸
AI-integrated imaging pipelinesThe molecular imaging market in the United States is driven by integration of AI-assisted image reconstruction and radiopharmaceutical innovation in oncology and neurology workflows. In the United States, hospitals and research centers increasingly focus on hybrid imaging systems combining PET/CT and PET/MR to streamline diagnostic accuracy while supporting personalized treatment planning and trial-based imaging protocols.
Segment Leadership and Growth Trends
Molecular Imaging Market Share (%), Modality, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportWithin the molecular imaging market, Single Photon Emission Computed Tomography (SPECT) held a 45.9% share in 2025, reflecting its established role in routine clinical imaging workflows. its position is underpinned by broad clinical familiarity, sustained use across diagnostic settings, and the practical advantage of being deeply integrated into existing nuclear medicine infrastructure. In the molecular imaging market, this installed base and operational comfort help SPECT maintain steady demand relative to other modalities that may require more specialized adoption pathways.
Nuclear Magnetic Resonance (NMR) Spectrometer is emerging as the fastest-growing modality in the molecular imaging market as demand rises for more advanced analytical and imaging capabilities. Its momentum is tied to growing interest in higher-resolution molecular characterization and the expanding need for tools that support more precise research and diagnostic evaluation. Compared with more mature modalities, NMR spectrometers are experiencing stronger uptake because they align well with evolving expectations for deeper molecular-level insight in both clinical and research environments.
End Use Segment Analysis: Hospitals (Largest Segment) vs Diagnostic Imaging Centers (Fastest-Growing Segment)
Hospitals accounted for the largest share of the molecular imaging market in 2025, underpinned by their central role in managing high patient volumes and offering integrated diagnostic services. Their leadership comes from the ability to house complex imaging infrastructure, support multidisciplinary care pathways, and absorb molecular imaging into broader treatment and diagnostic workflows. This makes hospitals the leading end-use setting in the molecular imaging market, especially where imaging decisions are closely tied to inpatient care, specialist consultation, and coordinated disease management.
Diagnostic Imaging Centers represent the fastest-growing end-use segment in the molecular imaging market as healthcare delivery continues shifting toward more specialized and workflow-efficient outpatient settings. Their growth is being driven by the practical appeal of focused imaging operations, faster scheduling, and increasing patient preference for dedicated diagnostic facilities outside large hospital systems. Relative to hospitals, these centers are gaining momentum because they can expand access to molecular imaging services in a more streamlined and flexible operating model.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Modality | Molecular Ultrasound Imaging, Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Nuclear Magnetic Resonance (NMR) Spectrometer, Others | Single Photon Emission Computed Tomography (SPECT) | Nuclear Magnetic Resonance (NMR) Spectrometer |
| End Use | Hospitals, Diagnostic Imaging Centers, Research Institutes | Hospitals | Diagnostic Imaging Centers |
| Application | Cardiovascular, Neurology, Oncology, Respiratory, Gastrointestinal | Oncology | Cardiovascular |
Competitive Landscape and Market Positioning
1. Siemens Healthineers AG (Germany)
2. GE HealthCare (United States)
3. Koninklijke Philips N.V. (Netherlands)
4. Canon Medical Systems Corporation (Japan)
5. Bruker Corporation (United States)
6. Shimadzu Corporation (Japan)
7. Mediso Ltd. (Hungary)
8. United Imaging Healthcare Co. Ltd. (China)
9. Cubresa Inc. (Canada)
10. Positron Corporation (United States)
The molecular imaging market is evolving through the integration of advanced diagnostic modalities that enhance disease detection at a molecular level. Collaborative innovation efforts are supporting more comprehensive imaging ecosystems. Research advancements continue to improve accuracy, resolution, and functional imaging capabilities.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Lantheus Holdings | Dec-25 | Lantheus agreed to acquire Life Molecular Imaging for up to $750 million. This acquisition incorporates the approved PET imaging agent Neuraceq into its portfolio, significantly strengthening the company’s competitive position and diagnostic capabilities within the neurodegenerative disease and molecular imaging markets. |
| Siemens Healthineers | Dec-25 | Siemens Healthineers finalized the acquisition of Novartis’ imaging unit for $223 million. This strategic move enhances the company’s PET radiopharmacy infrastructure and expands its production capacity for radiopharmaceuticals, directly supporting the integration of molecular imaging and targeted therapeutic workflows. |
| Bayer | Dec-25 | Bayer entered into agreements to acquire two investigational pan-amyloid molecular imaging agents from Attralus. The transaction marks a targeted expansion of Bayer’s diagnostic portfolio and aligns with its strategic focus on advancing cardiovascular precision medicine through integrated molecular imaging solutions. |
| Minerva Imaging | Dec-25 | Private equity firm Nordic Capital completed an investment in Minerva Imaging. The funding is intended to accelerate the company’s growth and operational scale, providing the financial support necessary to expand its research services and capabilities within the highly specialized molecular imaging sector. |
| United Imaging | Dec-25 | United Imaging launched the uMI Panvivo and uMI Panorama GS systems, alongside a new nuclear medicine AI solution. These product introductions, coupled with new European strategic partnerships, reflect an aggressive expansion of the company’s molecular imaging portfolio and a broader initiative to increase its regional market penetration. |
| GE HealthCare | Dec-25 | GE HealthCare expanded its research partnership with Stanford Radiology to establish a specialized Center of Excellence. The collaboration focuses on advancing innovation across molecular imaging, pharmaceutical diagnostics, and advanced modalities like MRI and CT, reinforcing the company's long-term technology development and research pipeline. |
| GE HealthCare | Nov-25 | OhioHealth Doctors Hospital expanded its clinical infrastructure by deploying GE HealthCare’s StarGuide SPECT/CT system. This installation enhances the facility’s molecular imaging throughput and diagnostic precision, supporting advanced patient care workflows in oncology, neurology, and cardiovascular medicine through high-end imaging technology. |
| Siemens Healthineers | Jun-24 | The U.S. FDA cleared the Biograph Trinion, a PET/CT scanner designed for high energy efficiency and optimized clinical performance. By lowering lifetime operational costs while providing broad clinical application versatility, this launch addresses the industry demand for more sustainable and cost-effective molecular imaging solutions. |
| Spectrum Dynamics | Oct-22 | Spectrum Dynamics introduced the VERITON-CT 400 Series, utilizing 360° CZT-based, wide-bore solid-state detector technology. This development marks a significant advancement in digital nuclear medicine, enabling the imaging of high-energy isotopes across total-body, cardiac, and neurological applications, thereby improving image quality and clinical versatility. |
| Positron Corporation | Jun-24 | Positron Corporation announced the sale and upcoming installation of its Attrius PET System. As a dedicated 2D quantitative PET scanner tailored specifically for nuclear cardiology, this deployment highlights the continued demand for specialized, high-resolution imaging equipment focused on addressing specific clinical segments within the broader molecular imaging market. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Molecular Imaging Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Molecular Imaging Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchWhat is the market valuation of molecular imaging?
What are the growth projections for the molecular imaging industry?
How is the rising burden of cancer and neurological disorders influencing demand for molecular imaging procedures?
How are hybrid imaging systems, AI-enabled diagnostics, and funding initiatives shaping molecular imaging adoption?
Why is SPECT the leading modality in the molecular imaging market?
Why are diagnostic imaging centers the fastest-growing end-use segment in the molecular imaging market?
Why is North America the largest regional market for molecular imaging?
What factors are supporting molecular imaging market growth in Asia Pacific?
Which companies dominate the molecular imaging landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization